home / stock / gsgtf / gsgtf short
Short Information | GenSight Biologics SA (OTCMKTS:GSGTF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 17,549 |
Total Actual Volume | 34,761 |
Short Trends | |
---|---|
Cover Days | 6 |
Short Days | 14 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 877 |
Average Short Percentage | 68.67% |
Is there a GSGTF Short Squeeze or Breakout about to happen?
See the GSGTF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
05-01-2023 | $0.8 | $0.8 | $0.8 | $0.8 | 1,000 | 1,000 | 100% |
10-19-2022 | $3.15 | $3.15 | $3.15 | $3.15 | 600 | 600 | 100% |
08-30-2021 | $9 | $9 | $9 | $9 | 707 | 100 | 14.14% |
08-24-2021 | $9 | $9 | $9 | $9 | 11,000 | 10,000 | 90.91% |
07-22-2021 | $9.9 | $9.9 | $9.9 | $9.9 | 200 | 200 | 100% |
07-16-2021 | $8 | $8 | $8 | $8 | 130 | 130 | 100% |
07-08-2021 | $9.5 | $9.5 | $9.5 | $9.5 | 150 | 150 | 100% |
07-06-2021 | $9.87 | $9.87 | $9.87 | $9.87 | 109 | 109 | 100% |
06-11-2021 | $11 | $11 | $11 | $11 | 500 | 400 | 80% |
06-10-2021 | $10.9 | $10.8 | $10.9 | $10.8 | 719 | 619 | 86.09% |
06-07-2021 | $10.9 | $10.9 | $10.9 | $10.9 | 177 | 161 | 90.96% |
06-04-2021 | $10.9 | $9.9 | $10.9 | $9.9 | 821 | 100 | 12.18% |
06-03-2021 | $9.76 | $10.9 | $10.9 | $9.76 | 6,100 | 900 | 14.75% |
06-02-2021 | $10.14 | $10.14 | $10.14 | $10.14 | 218 | 128 | 58.72% |
06-01-2021 | $10.1 | $10.4 | $10.4 | $10 | 1,454 | 101 | 6.95% |
05-26-2021 | $9.9 | $9.9 | $9.9 | $9.9 | 1,001 | 1,001 | 100% |
04-22-2021 | $9.2 | $9.2 | $9.2 | $9.2 | 400 | 400 | 100% |
01-29-2021 | $8.2251 | $8.28 | $8.28 | $8.2251 | 7,850 | 350 | 4.46% |
01-25-2021 | $8.45 | $8.3 | $8.45 | $8.3 | 600 | 100 | 16.67% |
01-22-2021 | $9.24 | $9.16 | $9.24 | $9.16 | 1,025 | 1,000 | 97.56% |
News, Short Squeeze, Breakout and More Instantly...
GenSight Biologics SA Company Name:
GSGTF Stock Symbol:
OTCMKTS Market:
Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the filing of its 2...
Advanced discussions ongoing to secure financing until resumption of early access program (AAC/AAP) expected in Q3 2024 Full alignment sought with regulatory agencies prior to launch of a global Phase III trial supporting both US and EU regulatory submissions for registration of LUMEVOQ ...
Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its financial calen...